Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2852W HIGH $1.65
Volume
2.29 M
Value Traded
2.29 M
Short % Float
7.5%
Days to Cover
1.0
-8.04%Week
-39.05%1 Month
-0.96%3 Month
-85.46%5 Year
-85.46%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
57.64 M
EPS (TTM)
-0.45
P/E Ratio
-
Ent. Value
29.99 M
Total Shares
55.96 M
Float Shares
57.42 M
Insiders
14.40%
Institutions
11.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
QTEX Catalyst Timeline
Dated clinical, regulatory and corporate events for QTREX Quantum Ltd.
Past FDA Catalysts and PDUFA Decisions
How QTEX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
QTREX Quantum Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every QTEX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HYLA Blood Sensor | continuous blood monitoring | 2025-03-04 | accuracy: 96%; oxygen deficiency accuracy: 92.3%; patients in study: 6Read More | Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy Inspira's AI-powered continuous blood monitoring technology demonstrated a high degree of accuracy in a keyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Parnes TalDirector | Buy | 6,666 766,666 held | $1.50 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QTEX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in QTEX for Q2 2026. | ||||
Ownership Trends
QTEX Short Interest
Shares sold short, counted twice a month.
7.5%
Short % of Float
of tradable shares sold short
4.3M
Shares Sold Short
+30.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
39.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QTEX ranks across every disease it competes in
Competitive Position is a premium feature
See how QTEX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQTEX News
QTEX▲ +5.8%on this news
QTREX Expands into Quantum Processor Interface with Single-Build Cryogenic Chip Carrier
QTREX Quantum Ltd. has achieved a significant milestone by producing a cryogenic chip carrier using its proprietary single-build AME process, following a design from a major U.S. technology company. This innovation expands QTREX's involvement within the quantum hardware ecosystem, integrating the chip carrier with the interconnect structure in one architecture. The new capability is expected to enhance signal transport and critical functions around quantum processors, positioning the company to address scaling challenges in future quantum computing systems. QTREX plans to showcase the chip carrier sample during Quantum.Tech World 2026 and tailor designs for specific customer requirements.
Read more →QTEX▲ +13.5%on this news
QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing
QTREX Quantum Ltd. has received a grant of approximately $1 million from the Israel Innovation Authority to develop a native RF dielectric material specifically designed for scalable superconducting quantum computing. This material aims to address critical challenges in radio frequency signal routing in cryogenic environments. The grant supports QTREX's vision of advancing its integration of materials and electronics to meet the unique demands of quantum connectivity. CEO Dagi Ben-Noon emphasized that conventional wiring architectures are inadequate for the scaling needs of superconducting quantum processors, underscoring the need for purpose-built solutions in the industry.
Read more →QTEXQTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials
QTREX Quantum Ltd. has announced a purchase order from a Fortune 500 company for an Additively Manufactured Electronics (AME) system and related materials. This order is expected to enhance QTREX's commercial footprint in the AME sector, reinforcing its position in advanced technology environments. The AME system will be delivered outside the United States, aiming to provide unique manufacturing capabilities that traditional technologies cannot achieve. CEO Dagi Ben-Noon emphasized the advantages of the AME platform, highlighting the company's growing commercial activity and engagement with tier-1 customers.
Read more →QTEXPricing of a $10 Million Private Placement of Ordinary Shares with a New Fundamental Institutional Investor
QTREX Quantum Ltd. has announced a $10 million private placement agreement with a fundamental institutional investor for 6,666,667 ordinary shares. The company plans to use the proceeds for working capital and general corporate purposes. The closing of the offering is anticipated around June 1, 2026. Company CEO Dagi Ben-Noon expressed optimism about this funding reinforcing their transition into a quantum hardware infrastructure company and advancing their additively manufactured electronics capabilities.
Read more →QTEX▲ +42.9%on this newsshared move
Additively Manufactured Electronics and Fabrica Product Lines (Product Lines of Nano Dimension Ltd.) Combined Abbreviated Financial Statements
QTREX Quantum Ltd. has undergone an audit of its financial statements related to the acquisition of certain assets and liabilities from Nano Dimension Ltd.'s Additively Manufactured Electronics and Fabrica product lines. The financial statements reveal a decline in revenues and assets, with significant losses and expenses reported for the years ending December 31, 2024 and 2025. There is considerable uncertainty surrounding the continued viability of the Acquired Operations due to ongoing financial losses and dependence on financial support from the acquiring company.
Read more →QTEXInspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker "QTEX" on May 20, 2026, Following Strategic Focus on AME and Quantum Connectivity
Inspira Technologies will start trading under the new ticker symbol 'QTEX' on May 20, 2026, as part of its corporate rebranding to QTREX Quantum Ltd. This change emphasizes the company's strategic focus on its Additively Manufactured Electronics platform, targeting improvements in quantum connectivity infrastructure. The rebranding aligns with Inspira's commitment to developing high-performance electronics solutions for sectors including defense and aerospace. Existing shareholders won't need to take any action during this transition.
Read more →QTEXLangone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation
Inspira Technologies has received a $580,000 purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems. This order follows a successful evaluation involving over 30 patients, affirming ART100's operational value in clinical settings. The purchase order marks a transition from evaluation to commercial procurement and enhances Inspira's position in ongoing discussions with other hospital systems. ART100 is currently under evaluation in additional hospitals across the U.S.
Read more →QTEXTechnologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan Israel, May 11, 2026 -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," "Inspira Technologies,"
Inspira Technologies has issued a letter from CEO Dagi Ben-Noon outlining a comprehensive strategic direction focused on value creation through its Additively Manufactured Electronics (AME) platform and quantum connectivity initiatives. The Company is shifting its operations from legacy medical activities to prioritize scalable revenue generation in high-demand sectors. Recent commercial achievements demonstrate significant interest and ongoing engagements with Tier-1 technology and defense customers. The move to rebrand as QTREX Quantum Ltd. aligns with its ambitious plans within the rapidly evolving quantum computing market.
Read more →QTEXInspira Secures $596,000 AME System Order from Leading Irish Technological University
Inspira Technologies has announced a $596,000 purchase order for its Additively Manufactured Electronics (AME) system from a prominent Irish technological university. This order, which includes a 40% non-refundable upfront payment, aims to support the university's advanced research in various cutting-edge domains. The deployment of the system is set to provide Inspira with a recurring revenue model through proprietary consumables and services, reinforcing its commercial strategy. The installation will also serve as a reference point for fostering future engagements with academic and commercial institutions across Europe.
Read more →QTEXInspira and Qarakal Sign Joint Development Agreement for Cryogenic Interconnects in Superconducting Quantum Systems
Inspira Technologies has entered into a Joint Development Agreement with Qarakal Quantum to enhance the performance of superconducting quantum systems. This collaboration focuses on testing Inspira's Additively Manufactured Electronics platform under cryogenic conditions, which is crucial for improving signal connectivity in quantum computing. The structured agreement includes a multi-phase engineering program that aims to address significant challenges in scaling quantum technology. This partnership is a strategic move for Inspira as it expands its capabilities within the quantum computing sector.
Read more →QTEXTechnologies Secures Fully Paid $390,000 Order and Recurring Revenue Stream from Premier APAC University
Inspira Technologies has secured a fully paid purchase order worth $390,000 for its additive manufacturing electronics system from a leading Asia-Pacific university. This agreement not only provides immediate revenue but also establishes a recurring revenue stream through consumables and service fees. The AME system is designed to support advanced quantum research, facilitating the development of high-performance electronics crucial for scaling quantum computing systems. Delivery and deployment of the system are scheduled in the coming weeks, accompanied by tailored training for the university's research teams.
Read more →QTEXInspira Completes Commercial Deployment of its AME System at a Tier-1 U.S. Defense Entity
Inspira Technologies OXY B.H.N. Ltd. announced the successful deployment of its Additively Manufactured Electronics (AME) system at a Tier-1 U.S. defense customer site. This milestone is seen as a significant achievement that confirms the demand for the AME platform in advanced defense operations and establishes a contractual basis for ongoing revenue. Although the identity of the customer remains undisclosed due to confidentiality, the engagement highlights the strategic importance of Inspira's technology in sectors like quantum computing and superconducting systems. The company expresses optimism about its financial future as this deployment could enhance its growth trajectory.
Read more →QTEXTechnologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion Israel, April 14, 2026-- Inspira Technologies OXY B.H.N. Ltd (NASDAQ: IINN,IINNW) ("Inspira Technologies" or the "Company")
Inspira Technologies has appointed Yoav Rozanovich as Chief Business Officer to lead its commercial strategy. His experience in additive manufacturing and advanced electronics is anticipated to drive immediate revenue growth and long-term success in the quantum computing sector. The company aims to take advantage of existing assets and industry relationships to create scalable revenue opportunities, especially following the acquisition of the Additive Manufacturing of Electronics business from Nano Dimension. This strategic hiring reflects Inspira's transition from planning to active commercial execution.
Read more →QTEXto the Company's Report of Foreign Private Issuer on Form 6-K, filed with the SEC on
Inspira Technologies Oxy B.H.N. Ltd. is scheduled to hold an Extraordinary General Meeting of Shareholders on May 6, 2026. The Board unanimously supports Proposal 1, which includes a potential name change to QTREX Ltd. Shareholders eligible to vote must be recorded by April 21, 2026, and can utilize proxies to participate. Important timelines for submitting additional agenda items and Position Statements are also provided, ensuring robust shareholder engagement.
Read more →QTEXInspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform
Inspira Technologies has announced its entry into the quantum computing sector by acquiring an additive manufactured electronics platform aimed at addressing critical connectivity challenges in dilution cryostats. The new 3D connectivity architecture is designed to enhance the stability and performance of quantum systems. With over $200 million invested in AME technology, Inspira is well-positioned to leverage its expertise and industry connections to pursue collaborations in the quantum space. The company aims to maintain its focus on existing medical initiatives while transitioning to a new corporate identity aligned with its quantum computing strategy.
Read more →QTEXInspira Technologies Announces Acquisition of the AME Platform from Nano Dimension
Inspira Technologies has announced the acquisition of the AME platform from Nano Dimension, which includes key intellectual property, advanced engineering capabilities, and various commercial assets. The acquisition is valued at up to $12.5 million, with an upfront payment of $2 million and additional performance-based payments. This move is aimed at enhancing Inspira's strategic position in high-value electronic applications as the company continues its existing medical business operations independently. A further strategic update is anticipated soon, highlighting the company's plans moving forward.
Read more →QTEXTechnologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase
Inspira Technologies has announced the termination of its sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd. The decision to end these financing facilities is aimed at maintaining a disciplined capital structure as the company prepares for its next strategic phase. Inspira is focusing on its commercial-stage medical device offerings, including the FDA-cleared INSPIRA ART100 system and the upcoming INSPIRA ART500. The company's advancements in proprietary blood monitoring technologies further strengthen its position in the life-support and MedTech landscape.
Read more →QTEXInspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates
Inspira Technologies reported its financial results for the full year 2025, highlighting significant advancements in commercial execution for its INSPIRA ART100 system. The company achieved vendor approval to enter procurement pathways and made strides in discussions with various medical systems. Despite a net loss increasing to $13.2 million, Inspira managed to secure $4.75 million through a registered direct offering, which will strengthen its liquidity and strategic operations for 2026. The company continues to expand its clinical deployment and is focusing on converting growing opportunities into revenue.
Read more →QTEXReceives Nasdaq Notification Regarding Minimum Market Value Deficiency
Inspira Technologies has received a notification from Nasdaq regarding its non-compliance with the minimum market value requirement of $35 million. The company has until August 18, 2026, to regain compliance by maintaining the required market value for a minimum of 10 consecutive business days. While currently trading under the symbol 'IINN', the potential for delisting poses a significant risk if compliance is not achieved.
Read more →QTEXInspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State
Inspira Technologies has announced the deployment of its ART100 system at a new leading academic medical center in New York, which is ranked among the top 10 hospitals in the state. This deployment is part of a structured evaluation aimed at defining clinical protocols and assessing broader adoption. The initiative highlights Inspira's strategy to expand its commercial footprint within the U.S. healthcare sector, building on previous FDA clearances and successful evaluations at major health facilities.
Read more →About QTREX Quantum Ltd.
HeadquartersRaanana
Founded2017
BIOPHARMAWATCH ELITE PLUS
Trade the next QTEX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime